title: Incretin based therapeutics: connections to vascular biology and implications for potential cardiovascular disease prevention: Editorial to: "Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation" by Dai et al.
authors.affiliation: Eastern Clinical Research Unit: Translational Research Division, Department of Medicine, Monash University, Level 2, 5 Arnold Street, Box Hill 3128, Melbourne, Australia, anthony.dear@monash.edu.
authors.forename: Anthony E
authors.initials: AE
authors.lastname: Dear
mesh_terms: D019332:Endothelin-1 / Q000037:antagonists & inhibitors*; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000494:pharmacology; D000067757:Glucagon-Like Peptide-1 Receptor; D061307:Human Umbilical Vein Endothelial Cells / Q000187:drug effects*; D006801:Humans; D000069450:Liraglutide; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D018027:Receptors, Glucagon / Q000819:agonists*
chemical_list: D019332:Endothelin-1; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D016328:NF-kappa B; D018027:Receptors, Glucagon; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1